Bevacizumab for Fallopian Tubes Cancer

Phase-Based Progress Estimates
Fallopian Tubes Cancer+6 More
Bevacizumab - Drug
What conditions do you have?

Study Summary

This trial is testing whether adding the drug bevacizumab to ixabepilone improves progression-free survival in patients with recurrent or persistent platinum-resistant/refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Eligible Conditions
  • Fallopian Tubes Cancer
  • Primary Peritoneal Cancer
  • Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 5 Years

5 Years
Progression-free survival (PFS) differences between Ixabepilone alone and Ixabepilone + Bevacizumab

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

22%vitreous hemorrhage
17%worsening of cataract
9%vitreous syneresis
9%posterior capsule opacification
4%colon cancer
4%cranial nerve VI palsy
This histogram enumerates side effects from a completed 2015 Phase 4 trial (NCT02036424) in the Bevacizumab ARM group. Side effects include: vitreous hemorrhage with 22%, worsening of cataract with 17%, vitreous syneresis with 9%, posterior capsule opacification with 9%, pyelonephritis with 4%.

Trial Design

2 Treatment Groups

1 of 2
Ixabepilone + Bevacizumab
1 of 2

Active Control

Experimental Treatment

78 Total Participants · 2 Treatment Groups

Primary Treatment: Bevacizumab · No Placebo Group · Phase 2

Ixabepilone + BevacizumabExperimental Group · 2 Interventions: Ixabepilone, Bevacizumab · Intervention Types: Drug, Drug
ActiveComparator Group · 1 Intervention: Ixabepilone · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,667 Previous Clinical Trials
21,074,599 Total Patients Enrolled
1 Trials studying Fallopian Tubes Cancer
31 Patients Enrolled for Fallopian Tubes Cancer
Alessandro D. Santin, MDPrincipal InvestigatorYale University

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients must have at least one target lesion to be used to assess response on this protocol as defined by RECIST v1.1.
You have a specimen available for immunohistochemistry for class III β-tubulin status
You have been optimally or sub-optimally debulked.
Patients with measurable recurrent disease of any previous stage (I-IV) are eligible to enrollment.
The diagnosis must be histologically confirmed by a gynecologic pathologist.
Absolute neutrophil count greater than or equal to 1500 cells/mm3.
Platelets greater than or equal to 100,000/uL.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: November 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.